Stryker Corporation (SYK) – Growing EPS is a positive sign

in Company Report, Healthcare & Life Sciences, Pharma & Biotech on October 21, 2021

Neurotechnology and Spine had organic growth of 15.5%. This growth reflects double digit performances in all four of Neurotech businesses: CMF, Neurovascular, Neurosurgical and ENT. It also
reflects very strong growth in neurovascular business of ~30%.

Highlights

Valuation

– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– DCF Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

Crispidea Coverage

No of Pages : 38

Release Information

  • Released
    :

    October 21, 2021

  • Last Updated
    :

    February 21, 2022